Quantitative mass spectrometry for colorectal cancer proteomics

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 42-54

  Martínez Aguilar, Juan ^a   Chik, Jenny ^a   Nicholson, Judith ^a   Semaan, Crystal ^a   Mckay, Matthew J ^a   Molloy, Mark P ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

Biomarker; Colorectal cancer (CRC); Mass spectrometry; Quantitation

Indexed keywords

ALPHA 1 ANTITRYPSIN; APC PROTEIN; CALVASCULIN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; FXYD2 PROTEIN; GLUTATHIONE TRANSFERASE M3; MUTANT PROTEIN; PROTEASOME; S100A11 PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BLOOD EXAMINATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER STAGING; CARCINOGENESIS; CELL FRACTIONATION; CELLULAR SECRETION; COLON POLYPOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DISEASE MODEL; EARLY DIAGNOSIS; ENZYME INHIBITION; FECES ANALYSIS; GENE MUTATION; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LYMPH NODE METASTASIS; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MUTATION; NONHUMAN; OCCULT BLOOD TEST; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; QUANTITATIVE MASS SPECTROMETRY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SELECTED REACTION MONITORING; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; UBIQUITINATION; WHOLE CELL;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; MASS SPECTROMETRY; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872689006     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200080     Document Type: Review

References (95)

1. Ferlay, J., Shin, H.-R., Bray, F., Forman, D. et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010, 127, 2893-2917.
2. Haggar, F. A., Boushey, R. P., Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg. 2009, 22, 191-197.
3. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA- Cancer J. Clin. 2012, 62, 10-29.
4. White, V., Miller, R., Colorectal cancer: prevention and early diagnosis. Medicine 2007, 35, 297-301.
5. Booth, R. A., Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007, 249, 87-96.
6. Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T. et al., Colorectal cancer. Lancet 2010, 375, 1030-1047.
7. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L. et al., Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 2007, 43, 1348-1360.
8. Newton, K. F., Newman, W., Hill, J., Review of biomarkers in colorectal cancer. Colorectal Dis. 2012, 14, 3-17.
9. Barderas, R., Babel, I., Casal, J. I., Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics- Clin. Appl. 2010, 4, 159-178.
10. Jimenez, C. R., Knol, J. C., Meijer, G. A., Fijneman, R. J. A., Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J. Proteomics 2010, 73, 1873-1895.
11. Thierolf, M., Hagmann, M.-L., Pfeffer, M., Berntenis, N. et al., Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics- Clin. Appl. 2008, 2, 11-22.
12. McKay, M. J., Sherman, J., Laver, M. T., Baker, M. S. et al., The development of multiple reaction monitoring assays for liver-derived plasma proteins. Proteomics-Clin. Appl. 2007, 1, 1570-1581.
13. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
14. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J. R. et al., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 2010, 7, 383-385.
15. Picotti, P., Rinner, O., Stallmach, R., Dautel, F. et al., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 2010, 7, 43-46.
16. Ludwig, C., Claassen, M., Schmidt, A., Aebersold, R., Estimation of absolute protein quantities of unlabeled samples by selected reaction monitoring mass spectrometry. Mol. Cell Proteomics 2012, 11, M111 013987.
17. Gallien, S., Duriez, E., Domon, B., Selected reaction monitoring applied to proteomics. J. Mass Spectrom. 2011, 46, 298-312.
18. Hüttenhain, R., Malmström, J., Picotti, P., Aebersold, R., Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 2009, 13, 518-525.
19. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G., An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 2010, 9, 184-196.
20. Sherman, J., McKay, M. J., Ashman, K., Molloy, M. P., How specific is my SRM?: the issue of precursor and product ion redundancy. Proteomics 2009, 9, 1120-1123.
21. Duncan, M. W., Yergey, A. L., Patterson, S. D., Quantifying proteins by mass spectrometry: the selectivity of SRM is only part of the problem. Proteomics 2009, 9, 1124-1127.
22. Geiger, T., Wehner, A., Schaab, C., Cox, J. et al., Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell Proteomics 2012, 11, M111 014050.
23. Zybailov, B., Coleman, M. K., Florens, L., Washburn, M. P., Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal. Chem. 2005, 77, 6218-6224.
24. Lundgren, D. H., Hwang, S. I., Wu, L., Han, D. K., Role of spectral counting in quantitative proteomics. Expert Rev. Proteomics 2010, 7, 39-53.
25. Neilson, K. A., Ali, N. A., Muralidharan, S., Mirzaei, M. et al., Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 2011, 11, 535-553.
26. Pham, T. V., Piersma, S. R., Oudgenoeg, G., Jimenez, C. R., Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev. Mol. Diagn. 2012, 12, 343-359.
27. Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
28. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
29. Unwin, R. D., Griffiths, J. R., Whetton, A. D., Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat. Protoc. 2010, 5, 1574-1582.
30. Thompson, A., Prescott, M., Chelebi, N., Smith, J. et al., Electrospray ionisation-cleavable tandem nucleic acid mass tag-peptide nucleic acid conjugates: synthesis and applications to quantitative genomic analysis using electrospray ionisation-MS/MS. Nucleic Acids Res. 2007, 35, e28.
31. De, L. V., Taylor, A. M., Li, W., Minkoff, M. S. et al., Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J. Proteome Res. 2008, 7, 3525-3534.
32. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. et al., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
33. Lottspeich, F., Kellermann, J., ICPL labeling strategies for proteome research. Methods Mol. Biol. 2011, 753, 55-64.
34. Hsu, J. L., Huang, S. Y., Chow, N. H., Chen, S. H., Stable-isotope dimethyl labeling for quantitative proteomics. Anal. Chem. 2003, 75, 6843-6852.
35. Hsu, J. L., Huang, S. Y., Chen, S. H., Dimethyl multiplexed labeling combined with microcolumn separation and MS analysis for time course study in proteomics. Electrophoresis 2006, 27, 3652-3660.
36. Bienz, M., Clevers, H., Linking colorectal cancer to Wnt signaling. Cell 2000, 103, 311-320.
37. McCart, A. E., Vickaryous, N. K., Silver, A., Apc mice: models, modifiers and mutants. Pathol. Res. Pract. 2008, 204, 479-490.
38. Rangiah, K., Tippornwong, M., Sangar, V., Austin, D. et al., Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J. Proteome Res. 2009, 8, 5153-5164.
39. Hung, K. E., Faca, V., Song, K., Sarracino, D. A. et al., Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev. Res. (Phila.) 2009, 2, 224-233.
40. Huttlin, E. L., Chen, X., Barrett-Wilt, G. A., Hegeman, A. D. et al., Discovery and validation of colonic tumor-associated proteins via metabolic labeling and stable isotopic dilution. Proc. Natl. Acad. Sci. USA 2009, 106, 17235-17240.
41. Wolters, D. A., Washburn, M. P., Yates, J. R., 3rd, An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 2001, 73, 5683-5690.
42. Zhu, W., Fang, C., Gramatikoff, K., Niemeyer, C. C. et al., Proteins and an inflammatory network expressed in colon tumors. J. Proteome Res. 2011, 10, 2129-2139.
43. Fijneman, R. J. A., de Wit, M., Pourghiasian, M., Piersma, S. R. et al., Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin. Cancer Res. 2012, 18, 2613-2624.
44. Ghosh, D., Yu, H., Tan, X. F., Lim, T. K. et al., Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J. Proteome Res. 2011, 10, 4373-4387.
45. Arielly, S. S., Ariel, M., Yehuda, R., Scigelova, M. et al., Quantitative analysis of caveolin-rich lipid raft proteins from primary and metastatic colorectal cancer clones. J. Proteomics 2012, 75, 2629-2637.
46. Luque-Garcia, J. L., Martinez-Torrecuadrada, J. L., Epifano, C., Canamero, M. et al., Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010, 10, 940-952.
47. Xue, H., Lü, B., Zhang, J., Wu, M. et al., Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J. Proteome Res. 2009, 9, 545-555.
48. Bauer, K. M., Lambert, P. A., Hummon, A. B., Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil. Proteomics 2012, 12, 1928-1937.
49. Tan, H. T., Tan, S., Lin, Q., Lim, T. K. et al., Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol. Cell. Proteomics 2008, 7, 1174-1185.
50. Ahn, Y. H., Kim, Y.-S., Ji, E. S., Lee, J. Y. et al., Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry. Anal. Chem. 2010, 82, 4441-4447.
51. Ahn, Y. H., Lee, J. Y., Lee, J. Y., Kim, Y.-S. et al., Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-Enrichment and SISCAPA with MRM mass spectrometry. J. Proteome Res. 2009, 8, 4216-4224.
52. Ahn, Y. H., Kim, K. H., Shin, P. M., Ji, E. S. et al., Identification of Low-abundance cancer biomarker candidate TIMP1 from serum with lectin fractionation and peptide affinity enrichment by ultrahigh-resolution mass spectrometry. Anal. Chem. 2011, 84, 1425-1431.
53. Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J. et al., Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. USA 2011, 108, 2444-2449.
54. Halvey, P. J., Ferrone, C. R., Liebler, D. C., GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J. Proteome Res. 2012, 11, 3908-3913.
55. Ruppen-Cañás, I., López-Casas, P. P., García, F., Ximénez-Embún, P. et al., An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics 2012, 12, 1319-1327.
56. Xie, L.-Q., Zhao, C., Cai, S.-J., Xu, Y. et al., Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J. Proteome Res. 2010, 9, 4701-4709.
57. Besson, D., Pavageau, A.-H., Valo, I., Bourreau, A. et al., A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol. Cell. Proteomics 2011, 10, doi:10.1074/mcp.M111.009712.
58. van der Flier, L. G., Haegebarth, A., Stange, D. E., van de Wetering, M., et al., OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 2009, 137, 15-17.
59. Meding, S., Balluff, B., Elsner, M., Schöne, C. et al., Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J. Pathol. 2012, doi:10.1002/path.4021.
60. Huang, L.-Y., Xu, Y., Cai, G.-X., Guan, Z.-Q. et al., S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J. Gastroenterol. 2011, 17, 69-78.
61. Mikula, M., Rubel, T., Karczmarski, J., Goryca, K. et al., Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct. Integr. Genomics 2011, 11, 215-224.
62. Wisniewski, J. R., Zougman, A., Nagaraj, N., Mann, M., Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6, 359-362.
63. Wiśniewski, J. R., Ostasiewicz, P., Mann, M., High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J. Proteome Res. 2011, 10, 3040-3049.
64. Jankova, L., Chan, C., Fung, C. L., Song, X. et al., Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol. Biosyst. 2011, 7, 2997-3005.
65. Kang, U.-B., Yeom, J., Kim, H.-J., Kim, H., Lee, C., Expression profiling of more than 3500 proteins of MSS-type colorectal cancer by stable isotope labeling and mass spectrometry. Proteomics 2012, 75, 3050-3062.
66. Watanabe, M., Takemasa, I., Kawaguchi, N., Miyake, M. et al., An application of the 2-nitrobenzenesulfenyl method to proteomic profiling of human colorectal carcinoma: a novel approach for biomarker discovery. Proteomics Clin. Appl. 2008, 2, 925-935.
67. Chen, J. S., Chen, K. T., Fan, C. W., Han, C. L. et al., Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J. 2010, 277, 3028-3038.
68. Han, C.-L., Chen, J.-S., Chan, E.-C., Wu, C.-P. et al., An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol. Cell. Proteomics 2011, doi:10.1074/mcp.M110.003087.
69. Albrethsen, J., Knol, J. C., Piersma, S. R., Pham, T. V. et al., Subnuclear proteomics in colorectal cancer. Mol. Cell. Proteomics 2010, 9, 988-1005.
70. Yang, H.-Y., Kwon, J., Park, H.-R., Kwon, S.-O. et al., Comparative proteomic analysis for the insoluble fractions of colorectal cancer patients. J. Proteomics 2012, 75, 3639-3653.
71. Yao, L., Lao, W., Zhang, Y., Tang, X. et al., Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J. Proteome Res. 2012, 11, 3281-3294.
72. Anderson, N. L., Anderson, N. G., The human plasma proteome. Mol. Cell. Proteomics 2002, 1, 845-867.
73. Hortin, G. L., Sviridov, D., Anderson, N. L., High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin. Chem. 2008, 54, 1608-1616.
74. Dennis, J. W., Laferte, S., Waghorne, C., Breitman, M. L. et al., Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987, 236, 582-585.
75. Ihara, S., Miyoshi, E., Ko, J. H., Murata, K. et al., Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching. J. Biol. Chem. 2002, 277, 16960-16967.
76. Whiteaker, J. R., Zhao, L., Zhang, H. Y., Feng, L.-C. et al., Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal. Biochem. 2007, 362, 44-54.
77. Murakoshi, Y., Honda, K., Sasazuki, S., Ono, M. et al., Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. 2011, 102, 630-638.
78. Matsubara, J., Honda, K., Ono, M., Sekine, S. et al., Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 2195-2203.
79. Fatime, N., Chelius, D., Luke, B. T., Yi, M. et al., Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients. Cancer Genomics Proteomics 2009, 6, 41-49.
80. Zhang, X., Xiao, Z., Liu, X., Du, L. et al., The potential role of ORM2 in the development of colorectal cancer. PLoS One 2012, 7, e31868.
81. Ang, C.-S., Nice, E. C., Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J. Proteome Res. 2010, 9, 4346-4355.
82. Ang, C.-S., Rothacker, J., Patsiouras, H., Gibbs, P. et al., Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis 2011, 32, 1926-1938.
83. Halvey, P. J., Zhang, B., Coffey, R. J., Liebler, D. C. et al., Proteomic consequences of a single gene mutation in a colorectal cancer model. J. Proteome Res. 2011, 11, 1184-1195.
84. 2-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17, 9-26.
85. Fearon, E. R., Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6, 479-507.
86. Ali, N. A., McKay, M. J., Molloy, M. P., Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol. Biosyst. 2010, 6, 2332-2338.
87. Chen, Y., Gruidl, M., Remily-Wood, E., Liu, R. Z. et al., Quantification of b-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J. Proteome Res. 2010, 9, 4215-4227.
88. Mallawaaratchy, D. M., Mactier, S., Kaufman, K. L., Blomfield, K. et al., The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. J. Proteomics 2012, 75, 1590-1599.
89. Nassif, N. T., Lobo, G. P., Wu, X., Henderson, C. J. A. et al., PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004, 23, 617-628.
90. Summy, J. M., Gallick, Gary E., Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003, 22, 337-358.
91. Leroy, C. d., Fialin, C., Sirvent, A., Simon, V. r. et al., Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates src invasive activity in advanced colon carcinoma cells. Cancer Res. 2009, 69, 2279-2286.
92. Organ, S. L., Tong, J., Taylor, P., St-Germain, J. R. et al., Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J. Proteome Res. 2011, 10, 3200-3211.
93. Bose, R., Molina, H., Patterson, A. S., Bitok, J. K. et al., Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc. Natl. Acad. Sci. USA 2006, 103, 9773-9778.
94. Liang, X., Hajivandi, M., Veach, D., Wisniewski, D. et al., Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 2006, 6, 4554-4564.
95. Ali, N. A., Molloy, M. P., Quantitative phosphoproteomics of transforming growth factor-β signaling in colon cancer cells. Proteomics 2011, 11, 3390-3401.